An observational study in Non-Small Cell Lung Cancer ALK-positive, sponsored by Pfizer. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Pfizer · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer — 15 open to participants now, 26 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Pfizer.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 13th largest by enrollment of the 17 observational ones that give a count, is one of 7 that started in 2026, is one of 17 observational ones, and was the 155th registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →15 of the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Australia, China and 11 more countries
Ages 18+
Pfizer · Sites in United States, China, France and 6 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 18 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
158 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 69 · Phase 2 58 · Phase 3 18 · Phase 4 4
First in 1999; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 160 across 1,151 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 79 across the 136 interventional studies, 97 across the 17 observational. Of the 123 that completed or were terminated, 70 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,338 studies on the registry; 147 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 393 (65%) have results posted.
4 of the studies in Carcinoma, Non-Small-Cell Lung by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07567352PfizerA Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment | 2027-03-01 |
| NCT04389632Seagen, a wholly owned subsidiary of PfizerA Study of Sigvotatug Vedotin in Advanced Solid Tumors | 2027-06-16 |
| NCT05538130PfizerA Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | 2027-08-31 |
| NCT05355701PfizerA Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this retrospective study is to learn about the real-world effects of the study medicine lorlatinib for the first-line treatment of Chinese adult patients who were diagnosed with ALK-positive a/mNSCLC.
The participants included in this study are:
In this study, the main objectives are to learn the patient characteristics and the real-world treatment pattern of first-line treatment of lorlatinib in China at a real-world setting.
Chinese adult patients who were diagnosed with ALK-positive a/mNSCLC, and initiated lorlatinib as first line treatment
Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lorlatinib
for the treatment of patients with locally advanced or metastatic ALK positive non-small cell lung cancer.
Age at Start of Lorlatinib Treatment
Number of percentages of patients by age
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Smoking status (if available) at Start of Lorlatinib Treatment
Number of patients by smoking status
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Histology of patients at start of Lorlatinib treatment
Histology of patients were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Eastern Cooperative Oncology Group (ECOG) performance status of patients at Start of Lorlatinib Treatment
number of Eastern Cooperative Oncology Group (ECOG) performance status of patients
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Initial cancer stage at diagnosis of patients prior Start of Lorlatinib Treatment
initial cancer stage of patients were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Current cancer stage at Start of Lorlatinib Treatment
Current cancer stage of patients were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Brain metastases status at Start of Lorlatinib Treatment
Brain metastases status of patients were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Date of initial NSCLC diagnosis
Date of initial NSCLC diagnosis
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Date of a/mNSCLC diagnosis
Date of a/mNSCLC diagnosis of patients were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
ALK-positive diagnosis prior to Start of Lorlatinib Treatment
Date of patients with ALK-positive diagnosis
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Gene testing method and results prior to initiation of lorlatinib treatment
Gene testing method and results of patients were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Date of brain metastases diagnosis prior to initiation of lorlatinib treatment
number and date of brain metastases diagnosis of patients for whom had BM prior lorlatinib treatment
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Presence of comorbidities at Start of Lorlatinib Treatment
Presence of comorbidities of patients were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Concomitant therapies at Start of Lorlatinib Treatment
Concomitant therapies of patients were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Date of lorlatinib initiation
Date of Lorlatinib first prescription were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Initial lorlatinib dose at Start of Lorlatinib Treatment
Initial lorlatinib dose for patients receiving Lorlatinb treatment were reported in this outcome measure
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Dose adjustments when patients were prescribed with Lorlatinib Treatment
Dose adjustments of Lorlatinib Treatment and Date were reported in this outcome measure
Time frame: From the date of initiation of lorlatinib treatment to the date of treatment dose adjustments, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
Gender at Start of Lorlatinib Treatment
Number of patients by gender
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Weight at Start of Lorlatinib Treatment
Number of patients by weight
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Height at Start of Lorlatinib Treatment
Number of patients by height
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Body mass index (BMI) at Start of Lorlatinib Treatment
Number of patients by BMI
Time frame: At initiation of lorlatinib treatment between July 2022- October 2024
Time to Discontinuation (TTD) in 1 L lorlatinib patients
Time to Discontinuation (TTD) was the time from the date of initiation of Lorlatinib Treatment to date if the permanent cessation of lorlatinib due to any reasons, including progression, adverse events, patient decision, or physician recommendation. TTD will be analyzed using Kaplan-Meier survival analysis.
Time frame: From the date of first lorlatinib dose until permanent discontinuation of treatment for any cause, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
Last dose for Patients who are still on the Lorlatinib first line treatment
Last dose for Patients who are still on the therapy were reported in this outcome measure
Time frame: the date of any-cause treatment discontinuation or study end, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
Treatment switching to other ALK TKls from Lorlatinib Treatment
Treatment switching to other ALK TKls was switching from lorlatinib to another ALK-TKIs due to any reasons. The Name of treatment regimen, Date of treatment switch and Duration of each switched regimen were recorded in this outcome measure.
Time frame: From the date of initiation of other ALK TKIs to the study end, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
1L lorlatinib resistance mechanism (if applicable)
Characterization of acquired resistance mechanisms to first-line lorlatinib, including on-target ALK alterations and off-target/bypass pathway activations, as identified at disease progression.
Time frame: From the date of initiation of lorlatinib treatment to the date of any-cause treatment discontinuation or study end, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
Treatment switching to subsequence treatment from 1L Lorlatinib Treatment
Treatment switching to subsequence treatment was switching from lorlatinib to another systemic therapy due to treatment failure caused by progression, intolerance, or physician decision. It was recorded in this outcome measure.
Time frame: From the date of initiation of subsequent other treatment to the date of any-cause treatment discontinuation or study end, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
Medical Costs during lorlatinib treatment period
Medical Costs during lorlatinib treatment period for patients were reported in this outcome measure, inducing drug costs, hospitalization costs, outpatient cost, and ect.
Time frame: From the date of first lorlatinib dose until permanent discontinuation of treatment for any cause, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
Brain metastases progression and date of patients receiving Lorlatinib treatment
Brain metastases progression was radiological confirmation of new or worsening intracranial lesions.
Time frame: From the date of initiation of lorlatinib treatment to the date of BM progression, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
Death (if applicable) of patients receiving Lorlatinib for the first-line treatment
percentage of Deaths (and date if applicable) of patients
Time frame: From the date of initiation of lorlatinib treatment to the date of any-cause treatment discontinuation or study end, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
The cumulative incidence rate of BM of patients receiving Lorlatinib for the first-line treatment
Percentage of number of patients with BM
Time frame: From the date of initiation of lorlatinib treatment to the date of any-cause treatment discontinuation or study end, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from May 2026 to primary completion in Sep 2026, 4 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Aug 2026 → Sep 2026 and completion Aug 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →